Navigation Links
InnerPulse, Inc. Appoints Elsa Chi Abruzzo as Vice-President of Regulatory and Quality Affairs
Date:3/6/2008

RESEARCH TRIANGLE PARK, N.C., March 6 /PRNewswire/ -- InnerPulse, Inc., a privately held company with a disruptive technology for the treatment of abnormal heart rhythms, announced the appointment of Elsa Abruzzo to the newly formed position of Vice-President of Regulatory and Quality Affairs. Ms. Abruzzo has more than 18 years of experience in the medical device industry including cardiac devices, such as heart valves, neurovascular embolic devices, and biomaterials.

Ms. Abruzzo, 40, most recently served as Vice-President Regulatory and Clinical Affairs with AtriCure, Inc., a manufacturer of cardiac ablation devices. Prior to that Elsa was with Percutaneous Valve Technologies, Inc. (PVT) where she served as head of regulatory and clinical affairs for a breakthrough percutaneous aortic valve technology. Prior to PVT, Elsa spent 10 years with CryoLife, Inc. (biomaterials, tissue heart valves and vascular grafts) and Cordis Johnson and Johnson (vascular devices), all in regulatory and quality affairs.

"We are delighted to have someone with Elsa's extensive experience join our executive team at this important juncture of the Company's evolution. She will have a key leadership role as we initiate our clinical studies and move closer to gaining regulatory approval of our novel defibrillator technology. Her experience in leading several technologies successfully through the regulatory approval process over the past 18 years will provide great value as the Company begins our clinical trials," said InnerPulse President and Chief Executive Officer Daniel A. Pelak.

Elsa is a graduate of the University of Miami with a degree in Industrial and Manufacturing Engineering.

About InnerPulse, Inc.

Founded in 2003, InnerPulse is a privately held, early-stage company pioneering a novel technology for those patients who have cardiac rhythm disorders. More information is available at http://www.
'/>"/>

SOURCE InnerPulse, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ventas Appoints James D. Shelton and Robert D. Reed to Board
2. Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer
3. China Sky One Medical, Inc. Appoints Four Independent Board Members
4. Stiefel Laboratories, Inc. Appoints New President
5. Asthma Foundation Appoints Award-Winning Scholar to Top Policy Position
6. New Jersey Hospital Association Names New Chairman, Appoints Board Officers and New Members
7. Belden Appoints Mary S. McLeod of Pfizer Inc. to Board of Directors
8. HealthpointCapital, LLC Appoints Stephen H. Hochschuler, M.D. as Clinical Advisor
9. CryoCath Appoints New Chief Financial Officer
10. Ceremed Appoints Vice President for Sales and Business Development
11. ScienceBased Health Appoints Anne L. Coleman, MD, PhD to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... more than 80 per cent of bowel cancers could ... that medicines called ,JAK inhibitors, halted tumour growth in ... in more than 80 per cent of bowel cancers. ... clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood ... second-most common cancer in Australia with nearly 17,000 people ...
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post ... , Senior citizens can purchase a joint life ... ones. A joint policy is cheaper, but will only ... , Life insurance can be used to cover important ... purchased online, as the application process is simple and ...
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... Join the more than 80 golfers who already have ... charity golf tournament to benefit Project HEAL, a not-for-profit organization ... afford treatment. The tournament will be held Monday, Oct. 6, ... The day-long event starts with 10:30 a.m. check-in and shotgun ... begin at 5 p.m. and will include an auction featuring ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... 6 The Foundation,for Taxpayer and Consumer Rights (FTCR) ... too much on what hospitals will pay in,fees for ... will cost,consumers., Yesterday, FTCR sent a letter to ... will be any limits placed on how much,individuals and ...
... presentation, BERKELEY HEIGHTS, N.J., Sept. 6 ... provider of software and,web-based services that enable enterprises ... business transactions, today,announced that it plans to report ... ended June 30, 2007 on Thursday, September 13, ...
... Mich., Sept. 6, 2007 Plexus Systems,Inc., providers ... today announced it has been named to the ... America. Plexus Systems, Inc. is ranked,at number 1581 ... http://www.newscom.com/cgi-bin/prnh/20070627/CLW071LOGO ) This is the ...
... Inc. (Nasdaq: IDIX ) announced today that management ... 20th Annual,Healthcare Conference on Tuesday, September 11th at 2:00 ... Conference on Thursday, September 20th at,3:30 p.m. (EDT), both ... The live and archived webcasts of the presentations can ...
... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) today filed ... Report on Form 10-K. The,filing of Par,s Form 10-K ... in restating its consolidated financial statements for certain,prior periods, ... file its,Form 10-Q for the first and second quarters ...
... Efforts to make open-heart,surgery a minimally invasive ... Institutes of Health Bioengineering Research Partnership award.,Professor ... Engineering,cardiac surgeon Pedro del Nido, M.D., at ... Microfabrica Inc. (Van Nuys,CA) will collaborate to ...
Cached Medicine News:Health News:Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007 2Health News:Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007 3Health News:Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226% 2Health News:Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226% 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 2Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 3Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 4Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 5Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 6Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 7Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 8Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 9Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 10Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 11Health News:Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting September 28, 2007 12Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2
(Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:9/30/2014)... , Sept. 30, 2014 /CNW/ - Protecting the health and safety ... Health Canada uses the appropriate powers and tools at its disposal ... safety and quality standards. To that end, Health ... stop the import into Canada of all ... . They are: , Apotex Pharmachem India Pvt ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... and sale of medical devices and homecare medical products in ... the first quarter of fiscal 2011 ended March 31, 2011 ... in the United States. Company management will ...
... LOUIS, April 27, 2011 Stereotaxis, Inc. (Nasdaq: ... of its new Stereotaxis Epoch™  platform, a comprehensive ... recognized benefits of remote magnetic catheter control, the ... power of the Odyssey platform, enabling highly sophisticated ...
Cached Medicine Technology:Dehaier Medical to Report First Quarter 2011 Financial Results on May 4 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 3Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 4
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
... (22° and 45° in both directions) linear ... transection and anastomosis., ,The stapler places ... and simultaneously the knife divides the tissue ... multiple use during a single surgical procedure: ...
... The ENDOPATH EZ45 No-Knife Endoscopic Linear Stapler ... minimally invasive surgical procedures for transection and ... line or tissue buttressing materials such as ... seven times for a total of eight ...
Improved Access in Open Procedures with Compact Endoscopic Linear Cutters., ,Staplers may be reloaded seven times for a total of eight firings. Different cartridges of the same size can be interchan...
Medicine Products: